Commercial Operations

ARTICLES

Fresenius Claims “Blatant Fraud” at Akorn Led It to Scuttle Merger

Fresenius claimed it discovered “blatant fraud at the very top level of Akorn’s executive team [and] stunning evidence of blatant and pervasive data integrity violations,” after it had agreed to acquire the company last year — leading to its decision to pull out of the planned $4.3 billion deal. Read More

PRODUCTS

Nine-Volume Title 21 CFR Set 2018

$585.00
The federal government has compiled the new 2018 CFR volumes.






View

Investigations Operations Manual 2018

$377.00
Don’t wait for FDA investigators to tell you what their new focus is when they’re already at your facility. Get a heads up with Investigations Operations Manual 2018. View

Real-World Serialization in Life Sciences — 2018 - Webinar Recording/Transcript

$287.00
The FDA is now regulating serialization under the Drug Supply Chain Security Act (DSCSA). And the FDA is not alone: Regulators worldwide, from Brazil and Argentina to South Korea and Saudi Arabia, are adding scrutiny of their own. View

Advertising & Promotion Hot Topics in Today’s FDA and FTC Landscape - Webinar Recording/ Transcript

$287.00
Drug and device advertising, marketing and promotion has come a long way from 30-second TV spots. These days the cutting edge is social media, product placement, engaging influencers, reality TV, pop-up shops and more. View

FDA’s New Concept of Operations for Drug Inspections & Evaluations - Webinar Recording/ Transcript

$287.00
ConOps is the acronym for a soon-to-take-place FDA restructuring that’s certain to affect drug inspections going forward. How will the agency’s new vertically integrated, programmatically aligned environment affect the new roles and responsibilities of CDER and ORA? View

The Opioid Crisis - Webinar Recording/Transcript

$287.00
The opioid crisis is out of control and drugmakers are in the crosshairs. The President is tweeting, the FDA has launched an Opioid Task Force, lawsuits are sprouting in courthouses across the land, and even local governments (Chicago is one) are investigating. View

Top Tips for Dealing with the FDA - Webinar Recording/Transcript

$287.00
The FDA is an inescapable presence in your life. It can be supportive and helpful one day, then turn on a dime and make life quite difficult indeed. But you have a say in the matter. You can control this all-important relationship to your advantage. View

Advertising & Promotion - Webinar Recording/Transcript

$287.00
Drug and device makers must advertise to survive, but the legal issues surrounding advertising and promotion are far from settled. FDA enforcement actions don’t seem to show a consistent pattern, leaving you to guess whether a warning letter lurks ahead and how to avoid it. View

Online Pharmacies — Impact on Regulatory & Quality - Webinar Recording/Transcript

$287.00
Websites selling junk drugs threaten the entire ethical drug business — manufacturers, suppliers, shippers, vendors, caregivers and patients too. It’s up to you to defend yourself. But how? View

Risk Evaluation and Mitigation Strategies (REMS) - Webinar Recording/Transcript

$287.00
Drugmakers’ latest Washington headache involves REMS. Changes are afoot inside the FDA and the halls of Congress, reaching all the way into the office of FDA Commissioner Gottlieb. View

Getting Real About Real World Evidence - Webinar Recording/Transcript

$287.00
Real world evidence — “RWE,” so-called — is making its way into your world. Sonali P. Gunawardhana Esq., one of the sharpest legal minds to emerge from the FDA in recent years, and Dr. Mary Jo Lamberti, a faculty member at Tufts CSDD, will walk you through the fast-moving RWE changes currently affecting the agency and business decisions alike. View

Choosing the Right Drug Approval Pathway - Webinar Recording/Transcript

$287.00
The 21st Century Cures Act has ushered in a new era of business friendliness. Helped along by a pro-business White House and Congress, the FDA wants to help get your new drugs to market. View